Login / Signup
[Elacestrant - ER+/HER2-, locally advanced, or metastatic breast cancer with an activating ESR1 mutation].
Lucie Houdou
Nicolas Kiavué
Published in:
Bulletin du cancer (2024)
Keyphrases
</>
metastatic breast cancer
locally advanced
estrogen receptor
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
signaling pathway
radiation therapy
phase ii study
endoplasmic reticulum
breast cancer cells
clinical trial
lymph node
open label